WallStreetZenWallStreetZen

Sectors & IndustriesHealthcareDrug Manufacturers - General
Best General Drug Manufacturer Stocks to Buy Now (2022)
Top general drug manufacturer stocks in 2022 ranked by overall Zen Score. See the best general drug manufacturer stocks to buy now, according to analyst forecasts for the drug manufacturers - general industry.

Industry: Drug Manufacturers - Gene...
Ticker
Company
Forecast Score
Market Cap
Price
Price Target
Upside/Downside
Consensus
Analysts
Fore. Revenue Growth
Fore. Earnings Growth
Forecast ROE
Forecast ROA
HZNP
HORIZON THERAPEUTICS PUBLIC LTD CO
$19.57B$85.13$133.3856.67%Strong Buy812.18%31.37%46.76%25.78%
GILD
GILEAD SCIENCES INC
$79.12B$63.08$69.4610.11%Hold11-3.59%20.40%41.92%13.24%
MRK
MERCK & CO INC
$235.51B$93.13$92.44-0.74%Buy103.65%12.54%54.74%20.98%
AMGN
AMGEN INC
$131.08B$245.37$240.92-1.81%Hold133.11%26.79%1,203.70%18.63%
PFE
PFIZER INC
$289.47B$51.59$57.4011.26%Buy10-8.28%-0.12%30.57%13.70%
JNJ
JOHNSON & JOHNSON
$479.68B$182.29$187.172.68%Buy63.26%14.64%41.74%17.48%
NVS
NOVARTIS AG
$187.69B$84.83N/AN/ASell21.44%-12.78%26.50%13.02%
BMY
BRISTOL MYERS SQUIBB CO
$168.11B$78.96$74.57-5.56%Hold91.60%43.48%58.11%17.81%
ABBV
ABBVIE INC
$269.20B$152.34$163.737.47%Buy110.11%18.21%140.65%15.99%
SNY
SANOFI
$135.00B$53.42N/AN/ABuy13.82%18.53%8.69%4.97%
LLY
ELI LILLY & CO
$309.39B$325.62$309.86-4.84%Strong Buy146.26%20.98%166.29%33.07%
GSK
GSK PLC
$117.68B$43.69N/AN/AHold2-0.98%14.02%130.77%23.59%
BIIB
BIOGEN INC
$31.04B$211.93$269.3927.11%Buy23-4.28%20.29%23.58%11.23%
GRFS
GRIFOLS SA
$8.24B$11.99N/AN/AHold116.47%106.53%20.96%6.02%
OGN
ORGANON & CO
$9.10B$35.86$37.173.64%Buy60.90%5.03%-127.02%14.98%
AZN
ASTRAZENECA PLC
$207.31B$66.90$75.0012.11%Hold37.02%N/A21.92%7.94%
TSVT
2SEVENTY BIO INC
$516.93M$13.74$44.00220.23%Strong Buy5N/AN/A-31.95%-16.78%
CRXT
CLARUS THERAPEUTICS HOLDINGS INC
$20.34M$0.39$10.202,508.70%Strong Buy5N/AN/A-5.14%4.27%

General Drug Manufacturer Stocks FAQ

What are the best general drug manufacturer stocks to buy right now in Jun 2022?

According to Zen Score, the 3 best general drug manufacturer stocks to buy right now are:

1. HORIZON THERAPEUTICS PUBLIC (NASDAQ:HZNP)


HORIZON THERAPEUTICS PUBLIC (NASDAQ:HZNP) is the top general drug manufacturer stock with a Zen Score of 72, which is 28 points higher than the general drug manufacturer industry average of 44. It passed 24 out of 33 due diligence checks and has strong fundamentals. HORIZON THERAPEUTICS PUBLIC has seen its stock lose -9.74% over the past year, underperforming other general drug manufacturer stocks by -12 percentage points.

HORIZON THERAPEUTICS PUBLIC has an average 1 year price target of $133.38, an upside of 56.67% from HORIZON THERAPEUTICS PUBLIC's current stock price of $85.13.

HORIZON THERAPEUTICS PUBLIC stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 8 analysts covering HORIZON THERAPEUTICS PUBLIC, 62.5% have issued a Strong Buy rating, 25% have issued a Buy, 12.5% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. GILEAD SCIENCES (NASDAQ:GILD)


GILEAD SCIENCES (NASDAQ:GILD) is the second best general drug manufacturer stock with a Zen Score of 65, which is 21 points higher than the general drug manufacturer industry average of 44. It passed 23 out of 38 due diligence checks and has strong fundamentals. GILEAD SCIENCES has seen its stock lose -6.1% over the past year, underperforming other general drug manufacturer stocks by -9 percentage points.

GILEAD SCIENCES has an average 1 year price target of $69.46, an upside of 10.11% from GILEAD SCIENCES's current stock price of $63.08.

GILEAD SCIENCES stock has a consensus Hold recommendation according to Wall Street analysts. Of the 11 analysts covering GILEAD SCIENCES, 18.18% have issued a Strong Buy rating, 18.18% have issued a Buy, 54.55% have issued a hold, while 0% have issued a Sell rating, and 9.09% have issued a Strong Sell.

3. MERCK & (NYSE:MRK)


MERCK & (NYSE:MRK) is the third best general drug manufacturer stock with a Zen Score of 56, which is 12 points higher than the general drug manufacturer industry average of 44. It passed 21 out of 38 due diligence checks and has strong fundamentals. MERCK & has seen its stock return 21.96% over the past year, overperforming other general drug manufacturer stocks by 20 percentage points.

MERCK & has an average 1 year price target of $92.44, a downside of -0.74% from MERCK &'s current stock price of $93.13.

MERCK & stock has a consensus Buy recommendation according to Wall Street analysts. Of the 10 analysts covering MERCK &, 40% have issued a Strong Buy rating, 10% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the general drug manufacturer stocks with highest dividends?

Out of 14 general drug manufacturer stocks that have issued dividends in the past year, the 3 general drug manufacturer stocks with the highest dividend yields are:

1. GRIFOLS SA (NASDAQ:GRFS)


GRIFOLS SA (NASDAQ:GRFS) has an annual dividend yield of N/A, which is N/A percentage points lower than the general drug manufacturer industry average of 3.11%. GRIFOLS SA's dividend payout is not stable, having dropped more than 10% six times in the last 10 years. GRIFOLS SA's dividend has not shown consistent growth over the last 10 years.

GRIFOLS SA's dividend payout ratio of 149.8% indicates that its dividend yield might not be sustainable for the long-term.

2. GSK (NYSE:GSK)


GSK (NYSE:GSK) has an annual dividend yield of 4.64%, which is 2 percentage points higher than the general drug manufacturer industry average of 3.11%. GSK's dividend payout is not stable, having dropped more than 10% ten times in the last 10 years. GSK's dividend has not shown consistent growth over the last 10 years.

GSK's dividend payout ratio of 86.4% indicates that its high dividend yield is sustainable for the long-term.

3. GILEAD SCIENCES (NASDAQ:GILD)


GILEAD SCIENCES (NASDAQ:GILD) has an annual dividend yield of 4.57%, which is 1 percentage points higher than the general drug manufacturer industry average of 3.11%. GILEAD SCIENCES's dividend payout is stable, having never dropped by more than 10% in the last 10 years. GILEAD SCIENCES's dividend has shown consistent growth over the last 10 years.

GILEAD SCIENCES's dividend payout ratio of 79.4% indicates that its high dividend yield is sustainable for the long-term.

Why are general drug manufacturer stocks up?

General drug manufacturer stocks were up 2.14% in the last day, and up 7.75% over the last week. SANOFI was the among the top gainers in the drug manufacturers - general industry, gaining 5.95% yesterday.

Sanofi shares are trading higher after the company and GSK announced data from their vaccine trial showing efficacy against the COVID-19 Omicron variant.

What are the most undervalued general drug manufacturer stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued general drug manufacturer stocks right now are:

1. GILEAD SCIENCES (NASDAQ:GILD)


GILEAD SCIENCES (NASDAQ:GILD) is the most undervalued general drug manufacturer stock based on WallStreetZen's Valuation Score. GILEAD SCIENCES has a valuation score of 71, which is 35 points higher than the general drug manufacturer industry average of 36. It passed 5 out of 7 valuation due diligence checks.

GILEAD SCIENCES's stock has dropped -6.1% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -9 percentage points.

2. HORIZON THERAPEUTICS PUBLIC (NASDAQ:HZNP)


HORIZON THERAPEUTICS PUBLIC (NASDAQ:HZNP) is the second most undervalued general drug manufacturer stock based on WallStreetZen's Valuation Score. HORIZON THERAPEUTICS PUBLIC has a valuation score of 57, which is 21 points higher than the general drug manufacturer industry average of 36. It passed 4 out of 7 valuation due diligence checks.

HORIZON THERAPEUTICS PUBLIC's stock has dropped -9.74% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -12 percentage points.

3. GRIFOLS SA (NASDAQ:GRFS)


GRIFOLS SA (NASDAQ:GRFS) is the third most undervalued general drug manufacturer stock based on WallStreetZen's Valuation Score. GRIFOLS SA has a valuation score of 57, which is 21 points higher than the general drug manufacturer industry average of 36. It passed 4 out of 7 valuation due diligence checks.

GRIFOLS SA's stock has dropped -31.45% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -34 percentage points.

Are general drug manufacturer stocks a good buy now?

38.89% of general drug manufacturer stocks rated by analysts are a buy right now. On average, analysts expect general drug manufacturer stocks to rise by 9.86% over the next year.

What is the average p/e ratio of the drug manufacturers - general industry?

The average P/E ratio of the drug manufacturers - general industry is 9.02x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.